DiagnOptics

DiagnOptics is a medical technology company based in the Netherlands that specializes in the non-invasive assessment of Advanced Glycation End-products (AGEs). The company's flagship product, the AGE Reader, utilizes skin autofluorescence to provide a rapid and reliable measure of AGE accumulation, which serves as a biomarker for metabolic and cardiovascular risks. This technology is primarily used in the management and screening of patients with diabetes, renal failure, and cardiovascular diseases. By quantifying tissue damage caused by glycation, DiagnOptics enables healthcare providers to identify high-risk patients and monitor the effectiveness of treatments. The company's solutions are backed by extensive clinical research and are used globally in both clinical practice and research settings.